News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2024
August 2024
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Our first WIM Speaker Spotlight for WIM Summit2024 – Women In Medicine
Photo from Women In Medicine/X
May 26, 2024, 14:10

Our first WIM Speaker Spotlight for WIM Summit2024 – Women In Medicine

Women In Medicine posted on X:

“Kicking off this holiday weekend with our first WIM Speaker Spotlight for WIM Summit2024! And what a great Woman In Medicine to kick off the week before ASCO!
Make sure you register for this years conference soon!”

Source: Women In Medicine/X

cancer OncoDaily Oncology Sandra Swain WIM Speaker Spotlight WIM Summit2024 women in medicine
Blog
Aug 12, 2024, 02:37
Biagio Ricciuti: Vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Blog
Aug 12, 2024, 02:33
Carmen Uscatu: When the meaning of the future lies in our past
Blog
Aug 12, 2024, 02:23
Rafael Fonseca: Defining CRS and ICANs risks
Blog
Aug 12, 2024, 02:15
Expert Working Group of EC-CvC will review cervical screening during a meeting at IARC
Blog
Aug 12, 2024, 02:14
Yale Cancer Center - Lymphir offers hope for Skin Disease in cutaneous T-cell lymphoma
Blog
Aug 12, 2024, 02:01
Maciej M Mrugala: Wonderful program for Early Career Professionals and Young Investigators
Blog
Aug 12, 2024, 01:52
Mainak Bardhan: Wonderful and busy start of the PhD program at University of Miami’s Miller School of Medicine
Blog
Aug 12, 2024, 01:50
From survivor to advocate: Kyle DeLeon's fight for equity in cancer care
Blog
Aug 12, 2024, 01:44
Jill Barnholtz-Sloan: Evolutionary Biomarkers to predict prostate cancer re-occurrence
Blog
Aug 12, 2024, 01:35
Joshua Zeidner: Highly impactful data for R/R AML and menin inhibitors
Blog
Aug 12, 2024, 01:34
Sachin H. Jain: The trend of health systems exiting the Medicare Advantage program
Blog
Aug 12, 2024, 01:27
Michael Ong received $2.4M for metastatic prostate cancer - CCTG